Trials / Terminated
TerminatedNCT00461682
Sb-705498 Rectal Pain Study
A Double-blind, Randomised, Placebo Controlled, Single Dose, Two-period Crossover Study to Investigate the Therapeutic Potential of the TRPV1 Antagonist SB-705498 in Treatment of Subjects With Rectal Hypersensitivity Including Irritable Bowel Syndrome.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
SB-705498 has demonstrated efficacy in several preclinical and human experimental pain models. This study will investigate the efficacy of SB-705498 in patients with rectal pain. This will be a double-blind, placebo-controlled, two-way crossover study. 21 patients with faecal urgency (Group 1), and 21 patients with IBS (Group 2) will complete this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SB-705498 |
Timeline
- Start date
- 2007-01-26
- Primary completion
- 2007-09-01
- Completion
- 2007-09-01
- First posted
- 2007-04-18
- Last updated
- 2018-08-20
- Results posted
- 2017-05-08
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00461682. Inclusion in this directory is not an endorsement.